" class="no-js "lang="en-US"> Novo Holdings - Medtech Alert
Thursday, March 28, 2024
Novo Holdings | Pharmtech Focus

Novo Holdings

About Novo Holdings

Novo Holdings

Novo Holdings A/S, a private limited liability company fully owned by the Novo Nordisk Foundation, is the holding company in the Novo Group, and responsible for managing the Foundation’s assets.

Besides being the major shareholder in the Novo Group companies Novo Nordisk A/S, Novozymes A/S and NNIT A/S, Novo Holdings provides seed and venture capital to development stage companies and takes significant ownership positions in well-established companies within life science, as well as manages a broad portfolio of financial assets.

Related Story

Novo Holdings Invests in US$105 Million Series C Funding of Alentis Therapeutics

April 13 2023

Novo Holdings A/S, a leading international life sciences investor, today announced it has participated in […]

Novo Holdings Leads $50 Million Investment in MedGenome to Accelerate Expansion Into New Markets and Deepen Product Offerings

August 30 2022

MedGenome, the leading genetic diagnostics, research, and data company in South Asia, announced today a […]

Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics

November 9 2021

Novo Holdings, a leading international life science investor, today announces that it has co-led the EUR […]

Novo Holdings Co-leads Hemab's US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

July 23 2021

Novo Holdings, a leading international life science investor, today announces that it has co-led alongside […]